



This is an official CDC HAN Info Service

Distributed via Health Alert Network April 15, 2013, 8:30 AM 10284-CHI-04-15-2013-TB

Nationwide Shortage of Tuberculin Skin Test Antigens: CDC Recommendations for Patient Care and Public Health Practice

Summary

TUBERSOL®, a product of Sanofi Pasteur Limited, is in shortage nationwide until at least the end of May 2013. TUBERSOL® is one of two purified-protein derivative (PPD) tuberculin products that are licensed by the United States Food and Drug Administration (FDA). The manufacturer notified CDC that 50-dose vials of TUBERSOL® are unavailable and that the supplies of 10-dose vials will be limited. This notice advises public health officials, clinicians, and workers in occupational health and infection control about how to adapt to the shortage.

JHP Pharmaceuticals, LLC, the manufacturer of APLISOL®, the other PPD tuberculin product that is licensed by FDA, has notified FDA that the product is on allocation and is available in restricted quantity. Acute local shortages of APLISOL® are being reported to CDC by healthcare providers who switch from TUBERSOL® to APLISOL®.

Background

Two kinds of immunological methods are used for detecting *Mycobacterium tuberculosis* infection: tuberculin skin tests (TSTs) and interferon-y release assay (IGRA) blood tests. The indications for using these tests are the same for the two methods, although one or the other method is preferred for certain populations (1), and this could play a factor in setting priorities when one of the methods is unavailable. Together, these tests are the only means for detecting latent *M. tuberculosis* infection, and they contribute to diagnosing tuberculosis (TB) disease. When findings such as chest radiography and mycobacterial cultures are sufficient for confirming or excluding the TB diagnosis, the results from a TST or an IGRA blood test might not be needed (2). However, most TB cases in the United States are diagnosed with a set of findings including results from one of these tests. When TB disease is strongly suspected, specific treatment should be started regardless of results from tuberculin skin test or an IGRA blood test (1,3).

In controlled studies, the concordance between TST results from TUBERSOL® and APLISOL® is high. The concordance between results from a TST and an IGRA blood test or between results from the two commercial IGRA blood tests is lower (1).

Recommendations

CDC recommends any of three general approaches for addressing the shortages of tuberculin skin test antigens:

1. Substitute IGRA blood tests for TSTs. The costs associated with using the blood tests can be

greater than the cost of TSTs. The blood tests require phlebotomy, preparation of blood specimens, and specific laboratory services for analysis. Thus, these tests are not available in all practice settings. Clinicians who use the IGRA blood tests should be aware that the criteria for test interpretation are different than the criteria for interpreting TSTs (1).

- 2. Allocate TSTs to priority indications, such as TB contact investigations, as determined by public health authorities. This might require deferment of testing some persons. CDC does not recommend testing persons who are not at risk of TB (4).
- 3. Substitute APLISOL® for TUBERSOL® for skin testing. In cross-sectional studies, the two products give similar results for most patients. Shortages of APLISOL® are expected to become more widespread, thus limiting the feasibility of this approach.

Some surveillance programs for TB infection control rely on routine serial TSTs. Switching products or methods might make serial changes in test results difficult to interpret: the apparent conversions of results from negative to positive or reversions from positive to negative could be caused by inherent inter-product or inter-method discordance (1,5). In settings with a low likelihood of TB exposure, the deferment of routine serial testing should be considered in consultation with public health and occupational health authorities.

References

- CDC. Updated guidelines for using interferon gamma release assays to detect *Mycobacterium tuberculosis* infection United States, 2010. MMWR 2010;59 (RR-5). http://www.cdc.gov/mmwr/PDF/rr/rr5905.pdf.
- 2. American Thoracic Society. Diagnostic standards and classification of tuberculosis in adults and children. Am J Respir Crit Care Med 2000;161:1376–95. http://www.cdc.gov/tb/publications/PDF/1376.pdf.
- 3. CDC. Treatment of tuberculosis. MMWR 2003;52(RR-11). http://www.cdc.gov/mmwr/PDF/rr/rr5211.pdf.
- 4. CDC. Targeted tuberculin testing and treatment of latent tuberculosis infection. MMWR 2000;49(RR-6). http://www.cdc.gov/mmwr/PDF/rr/rr4906.pdf.
- 5. CDC. Guidelines for preventing the transmission of *Mycobacterium tuberculosis* in health-care settings, 2005. MMWR 2005;54(RR-17) http://www.cdc.gov/mmwr/pdf/rr/rr5417.pdf.

The Centers for Disease Control and Prevention (CDC) protects people's health and safety by preventing and controlling diseases and injuries; enhances health decisions by providing credible information on critical health issues; and promotes healthy living through strong partnerships with local, national, and international organizations.

DHEC contact information for reportable diseases and reporting requirements

Reporting of diseases is consistent with South Carolina Law requiring the reporting of diseases and conditions to your state or local public health department. (State Law # 44-29-10 and Regulation # 61-20) as per the DHEC 2013 List of Reportable Conditions available at: http://www.scdhec.gov/health/disease/reportables.htm

Federal HIPAA legislation allows disclosure of protected health information, without consent of the individual, to public health authorities to collect and receive such information for the purpose of preventing or controlling disease. (HIPAA 45 CFR §164.512).

Regional Public Health Offices – 2013

Mail or call reports to the Epidemiology Office in each Public Health Region.

Region I Anderson, Oconee

220 McGee Road Anderson, SC 29625 Phone: (864) 260-4358 Fax: (864) 260-5623

Nights / Weekends: 1-866-298-4442

Abbeville, Edgefield, Greenwood, Laurens, McCormick, Saluda

1736 S. Main Street Greenwood, SC 29646 Phone: 1-888-218-5475 Fax: (864) 942-3690

Nights / Weekends: 1-800-420-1915

Region 2 Greenville, Pickens

PO Box 2507 200 University Ridge Greenville, SC 29602-2507 Phone: (864) 372-3133 Fax: (864) 282-4373

Nights / Weekends: (864) 809-3825

Cherokee, Spartanburg, Union

PO Box 4217 151 E. Wood Street Spartanburg, SC 29305-4217 Phone: (864) 372-3133 Fax: (864) 282-4373 Nights / Weekends: (864) 809-3825

Region 3

Chester, Lancaster, York

PO Box 817 1833 Pageland Highway Lancaster, SC 29720 Phone: (803) 286-9948 Fax: (803) 286-5418

Health Update

Nights / Weekends: 1-866-867-3886

Region 3 (continued)

Fairfield, Lexington, Newberry, Richland 2000 Hampton Street

Columbia, SC 29204 Phone: (803) 576-2749 Fax: (803) 576-2993

Nights / Weekends: 1-888-554-9915

Region 4

Chesterfield, Darlington, Dillon, Florence, Marlboro, Marion

145 E. Cheves Street Florence, SC 29506 Phone: (843) 661-4830 Fax: (843) 661-4859

Nights / Weekends: (843) 601-7051

Clarendon, Kershaw, Lee, Sumter

PO Box 1628 105 North Magnolia Street Sumter, SC 29150 Phone: (803) 773-5511 Fax: (803) 775-9941

Nights/Weekends: 803-458-1847

Region 5 Bamberg, Calhoun, Orangeburg

PO Box 1126 1550 Carolina Avenue Orangeburg, SC 29116 Phone: (803) 268-5833 Fax: (803) 533-7134

Nights / Weekends: (803) 535-9265

Aiken, Allendale, Barnwell

222 Beaufort Street, NE Aiken, SC 29801 Phone: (803) 642-1618 Fax: (803) 643-8386

Nights / Weekends: (803) 645-8167

Region 6

Georgetown, Horry, Williamsburg

1931 Industrial Park Road Conway, SC 29526-5482 Phone: (843) 915-8804 Fax: (843) 365-0085

Nights/Weekends: (843) 340-4754

Region 7

Berkeley, Charleston, Dorchester

4050 Bridge View Drive, Suite 600 N. Charleston, SC 29405 Phone: (843) 953-0047 Fax: (843) 953-0051

Nights / Weekends: (843) 219-8470

Region 8

Beaufort, Colleton, Hampton, Jasper

219 S. Lemacks Street Walterboro, SC 29488 Phone: (843) 441-1091 Fax: (843) 549-6845

Nights / Weekends: 1-843-441-1091

<u>DHEC Bureau of Disease Control</u> Division of Acute Disease Epidemiology

1751 Calhoun Street Box 101106 Columbia, SC 29211 Phone: (803) 898-0861 Fax: (803) 898-0897

Nights / Weekends: 1-888-847-0902



www.scdhec.gov

Categories of Health Alert messages:

Health Alert Conve Health Advisory Provid

Conveys the highest level of importance; warrants immediate action or attention.

Provides important information for a specific incident or situation; may not require immediate action. Provides updated information regarding an incident or situation; unlikely to require immediate action.

Info Service Does not require immediate action; provides general public health information.